This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
Pacira (PCRX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PCRX or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. CTLT: Which Stock Is the Better Value Option?
Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock
by Zacks Equity Research
Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra
PCRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
5 Best Stocks to Buy in a Coronavirus-Led Bear Market
by Tirthankar Chakraborty
The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.
Why Pacira (PCRX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)
The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group
Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall
by Supriyo Bose
Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.
3 Reasons Why Pacira (PCRX) Is a Great Growth Stock
by Zacks Equity Research
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
PCRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Top Ranked Momentum Stocks to Buy for February 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
3 Top-Ranked Stocks Poised for an Earnings Beat
by Sanghamitra Saha
Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
by Zacks Equity Research
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Will Pacira BioSciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Pacira BioSciences.